Market News (Page 1) - TendieTensor

Market News Page 1 of 293 • 7,302 articles

Salem Media Announces the Promotion of Carolyn Cassidy to Vice President

GlobeNewswire Inc. • Na

Salem Media Announces the Promotion of Carolyn Cassidy to Vice President

01/14/2026 03:00 PM • Salem Media announced the promotion of Carolyn Cassidy to Vice President & Regional General Manager. Cassidy will continue overseeing Salem's operations in Columbus, Tampa, Orlando, and Miami while joining the company's Senior Leadership Team. The promotion reflects Salem's commitment to developing strong leaders.

FMC - Develops, manufactures, and packages crop protection products, well-aligned with market expansion trends
SALM - The promotion of an experienced internal leader to VP level demonstrates organizational strength, continuity, and confidence in management talent. The emphasis on Cassidy's successful track record across multiple large markets and her addition to the senior leadership team suggests operational stability and growth potential.

#promotion #leadership #regional management #market operations #senior leadership team

AGILON HEALTH CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Agilon Health, Inc. Investors to Contact the Firm Before the March 2nd Lead Plaintiff Deadline

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

AGILON HEALTH CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Agilon Health, Inc. Investors to Contact the Firm Before the March 2nd Lead Plaintiff Deadline

01/14/2026 02:59 PM • A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding 2025 guidance and overstating financial impacts from strategic actions. Investors who purchased Agilon securities between February 26, 2025 and August 4, 2025 can apply to be lead plaintiff by March 2, 2026.

BALL - Provides aluminum packaging not typical for pesticide containers
AGL - The company is accused of issuing false 2025 guidance, overstating financial impacts from strategic actions, and making materially misleading statements about its business and operations, resulting in investor losses.

#class action lawsuit #securities fraud #false guidance #misleading statements #investor losses #lead plaintiff deadline

ARDT Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardent Health, Inc. Class Action Lawsuit

GlobeNewswire Inc. • Robbins Llp

ARDT Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardent Health, Inc. Class Action Lawsuit

01/14/2026 02:36 PM • Robbins LLP announced a class action lawsuit against Ardent Health, Inc. (ARDT) for allegedly misleading investors regarding accounts receivable and insufficient malpractice insurance. The company revealed a $43 million revenue decrease in Q3 2025 after transitioning to a new accounting system, causing the stock to plummet 34% from $14.05 to $9.30 per share on November 12-13, 2025. The lead plaintiff deadline is March 9, 2026.

ARDT - The company is facing a class action lawsuit for allegedly misleading investors about accounts receivable and insurance coverage. A significant $43 million revenue adjustment and 34% stock price decline indicate serious financial and operational issues, along with potential investor fraud.

#class action lawsuit #accounts receivable #revenue restatement #accounting system #stock decline #malpractice insurance

NAVAN ALERT: Bragar Eagel & Squire, P.C. is Investigating Navan, Inc. on Behalf of Navan Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

NAVAN ALERT: Bragar Eagel & Squire, P.C. is Investigating Navan, Inc. on Behalf of Navan Stockholders and Encourages Investors to Contact the Firm

01/14/2026 02:36 PM • Law firm Bragar Eagel & Squire is investigating Navan Inc. for potential securities law violations following the company's disappointing third quarter fiscal 2026 results, which revealed a $79 million GAAP operating loss compared to $19 million the prior year, and the immediate departure of its CFO just six weeks after the company's October 2025 IPO at $25 per share. The stock fell 11.9% to $12.90 on the news.

NAVN - Company experienced significant deterioration in financial performance with operating losses increasing from $19M to $79M year-over-year, CFO departure immediately after IPO, substantial stock price decline of 11.9% following earnings announcement, and ongoing securities investigation by law firm regarding potential violations of federal securities laws.

#securities investigation #IPO #operating loss #CFO departure #stock price decline #shareholder lawsuit #financial results

Broadcom Stock Plummets As Beijing's Security Directive Strikes

Benzinga • Evette Mitkov

Broadcom Stock Plummets As Beijing's Security Directive Strikes

01/14/2026 02:34 PM • Broadcom shares fell 5.40% after Chinese regulators instructed domestic companies to phase out cybersecurity software from U.S. and Israeli firms, including Broadcom-owned VMware, Palo Alto Networks, Fortinet, and Check Point Software, citing national security concerns over potential data collection.

CBRE - Advancing net-zero strategy by integrating low-carbon technologies, expanding electrification, and delivering science-based targets
AVGO - Stock declined 5.40% due to Chinese regulatory directive targeting its VMware subsidiary. The ban threatens revenue from Chinese operations and signals escalating U.S.-China tech tensions.

#China cybersecurity ban #U.S.-China tech tensions #VMware #cybersecurity software #national security #stock decline

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Semrush Holdings, Inc. (NYSE – SEMR)

GlobeNewswire Inc. • Brodsky & Smith

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Semrush Holdings, Inc. (NYSE – SEMR)

01/14/2026 02:31 PM • Law firm Brodsky & Smith is investigating potential breaches of fiduciary duty by Semrush Holdings' Board of Directors regarding the company's sale to Adobe for $12.00 per share ($1.9 billion total). The investigation questions whether the board conducted a fair process and whether the deal price provides fair value to shareholders, noting the offer is below the 52-week high of $18.74.

JCI - Leading in energy-efficient technologies, committed to long-term climate goals, and developing innovative solutions for sustainable infrastructure
SEMR - The company is under investigation for potential board misconduct in its acquisition by Adobe. The deal price of $12.00 per share is significantly below the 52-week high of $18.74, suggesting shareholders may have received unfair value, which raises concerns about fiduciary duty breaches.

#fiduciary duty #shareholder investigation #acquisition #deal valuation #class action lawsuit

BuildingReports and LIV Announce Integration Partnership to Simplify Fire Compliance Reporting

GlobeNewswire Inc. • Unknown

BuildingReports and LIV Announce Integration Partnership to Simplify Fire Compliance Reporting

01/14/2026 02:00 PM • BuildingReports and LIV announced a new integration partnership that allows inspection data to flow directly from BuildingReports into LIV's compliance platform. The integration eliminates manual reporting steps, reduces administrative burden for service companies, and provides AHJs and facility managers with seamless access to inspection reports at no additional cost to BuildingReports members.

BSX - Received expanded FDA indication for WaveWriter SCS Systems, demonstrated strong clinical trial results
CHYL - The partnership enhances LIV's compliance platform by connecting it with a major inspection data provider, improving data flow and user experience for its AHJ customers. This integration strengthens its competitive position in the fire safety compliance market.

#fire safety #inspection reporting #compliance software #integration partnership #AHJ #ITM compliance #automation

JBDI Holdings Announces Receipt of Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

GlobeNewswire Inc. • Jbdi Holdings Limited

JBDI Holdings Announces Receipt of Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

01/14/2026 01:52 PM • JBDI Holdings Limited (Nasdaq: JBDI) announced it received a delisting notice from Nasdaq on January 7, 2026, due to failure to maintain the minimum bid price of $1.00 over 30 consecutive business days. The company has 180 calendar days until July 6, 2026, to regain compliance. If unsuccessful, it may be eligible for an additional 180-day compliance period if it meets other listing standards, or face delisting.

ABT - Introduced Proclaim Plus system with multi-area pain coverage, but less prominent in the article compared to other companies
JBDI - The company received a delisting notice from Nasdaq for failing to maintain the minimum $1.00 bid price requirement. While the company has 180 days to regain compliance and the stock remains listed, the notice indicates financial distress and regulatory non-compliance, which poses a significant risk to shareholders and the company's market standing.

#delisting notice #minimum bid price requirement #Nasdaq Capital Market #compliance period #reverse stock split #listing standards

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

01/14/2026 01:33 PM • Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.

SKYE - The company's lead drug candidate failed to meet primary endpoints in clinical trials, resulting in a 60% stock price decline. The failure to achieve weight loss compared to placebo and lower than expected drug exposure indicate significant setbacks for the company's pipeline and investor value.

#class action lawsuit #Skye Bioscience #nimacimab #Phase 2a trial failure #stock price decline #securities fraud #investor losses

Winnebago Industries Showcases Bold New RV Innovations Across Premium Brands at Florida RV SuperShow

GlobeNewswire Inc. • Na

Winnebago Industries Showcases Bold New RV Innovations Across Premium Brands at Florida RV SuperShow

01/14/2026 01:31 PM • Winnebago Industries showcased its latest recreational vehicle innovations at the Florida RV SuperShow, featuring new models across its premium brands including Winnebago, Grand Design RV, and Newmar. Highlights include the debut of the Winnebago Sunflyer Class C RV, Grand Design's Foundation 42GD destination trailer, and Newmar's Freedom Aire compact luxury coach. The company emphasized its commitment to innovation, safety features, and smart connectivity across various price points.

BAYRY - Produces and packages crop protection products, directly benefiting from agricultural packaging market growth
WGO - The company is actively launching multiple new products and models across its three premium brands, demonstrating strong innovation pipeline and market expansion. The emphasis on cutting-edge features, safety, and customer-focused design indicates robust business activity and competitive positioning in the RV market.

#RV industry #product innovation #motorhomes #travel trailers #luxury coaches #outdoor lifestyle #new model launches

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

GlobeNewswire Inc. • Delveinsight

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

01/14/2026 01:00 PM • The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

NVS - FABHALTA (iptacopan) is positioned as a potentially first-in-class oral complement inhibitor for advanced gMG management with Phase III data expected by 2027, addressing significant unmet needs in refractory disease.

#generalized myasthenia gravis #immunotherapy #complement inhibitors #FcRn antagonists #CAR T-cell therapy #autoimmune disease #drug pipeline #clinical trials

ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

01/14/2026 12:58 PM • The Schall Law Firm is investigating Abacus Global Management, Inc. (NYSE: ABX) for potential securities violations following a Morpheus Research report alleging the company manipulated portfolio valuation methodology and used questionable life expectancy calculation methods to inflate profitability. The firm is seeking shareholders who suffered losses to participate in the investigation.

ABX - The company is under investigation for issuing false/misleading statements, manipulating valuation methodologies to appear more profitable, using questionable life expectancy estimates, and co-founders have documented red flags. These allegations suggest serious accounting fraud and investor deception.

#securities fraud #false statements #portfolio valuation #life settlements #accounting scheme #shareholder litigation #SPAC

AVNW Investors Have Opportunity to Join Aviat Networks, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

AVNW Investors Have Opportunity to Join Aviat Networks, Inc. Fraud Investigation with the Schall Law Firm

01/14/2026 12:57 PM • The Schall Law Firm is investigating Aviat Networks, Inc. (NASDAQ: AVNW) for potential securities law violations, alleging the company issued false or misleading statements and failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.

IONQ.WS - High cash burn, minimal revenue, continuous stock issuances, and speculative trading without meaningful commercial applications
AVNW - The company is under investigation for alleged securities law violations, including issuing false/misleading statements and failing to disclose material information to investors, which directly harms shareholder value and investor confidence.

#securities fraud #shareholder litigation #false statements #disclosure violations #class action lawsuit

CVS/Aetna Medicare Advantage Plans Policy Holders Have Opportunity to Join Investigation into Improper Claim Denial for Post-Acute Care with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

CVS/Aetna Medicare Advantage Plans Policy Holders Have Opportunity to Join Investigation into Improper Claim Denial for Post-Acute Care with the Schall Law Firm

01/14/2026 12:55 PM • The Schall Law Firm is investigating CVS Health Corporation's Aetna Medicare Advantage plans for potentially wrongfully denying prior authorizations for post-acute care using artificial intelligence without proper medical professional review, as required by contracts. The investigation covers claims from November 2019 to present, and CVS's AI practices have recently drawn scrutiny from the U.S. Senate.

RGTIW - CEO selling stock, primarily in R&D phase, years away from meaningful revenue
CVS - CVS is the subject of a formal investigation by a national litigation firm for allegedly breaching contracts by using AI to deny post-acute care claims without required medical professional review. The conduct has drawn U.S. Senate scrutiny, indicating potential regulatory and legal risks.

#CVS Health #Aetna Medicare Advantage #claim denial #prior authorization #artificial intelligence #post-acute care #breach of contract #investigation

TMSNY Investors Have Opportunity to Join Temenos AG Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

TMSNY Investors Have Opportunity to Join Temenos AG Fraud Investigation with the Schall Law Firm

01/14/2026 12:55 PM • The Schall Law Firm announced an investigation into Temenos AG for potential securities law violations, focusing on whether the company issued false or misleading statements or failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.

RGTI - CEO selling stock, primarily in R&D phase, years away from meaningful revenue
TMSNY - The company is under investigation for potential securities law violations, including issuing false/misleading statements and failing to disclose material information, which indicates serious compliance concerns and potential investor harm.

#securities litigation #shareholder rights #false statements #disclosure violations #class action lawsuit

BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

01/14/2026 12:53 PM • The Schall Law Firm is investigating Beta Bionics, Inc. for potential securities law violations, alleging the company issued false or misleading statements regarding patient starts. Beta Bionics disclosed lower-than-expected patient numbers on January 8, 2026, causing its stock to plummet over 37% the following day. The firm is seeking shareholders who suffered losses to participate in the investigation.

QBTS - Overvalued stock with high price-to-sales multiple and limited commercial quantum computing applications
BBNX - The company is under investigation for potential securities fraud involving false or misleading disclosures about patient starts. The stock experienced a severe 37% decline following the announcement of lower-than-expected patient numbers, indicating significant loss of investor confidence and potential regulatory violations.

#securities fraud #shareholder litigation #Beta Bionics #stock decline #misleading statements #patient starts #class action lawsuit

JP Morgan Stock To Remain 'Range Bound' Until Clarity On Credit Card APR: Analyst

Benzinga • Lekha Gupta

JP Morgan Stock To Remain 'Range Bound' Until Clarity On Credit Card APR: Analyst

01/14/2026 12:52 PM • JPMorgan Chase reported Q4 earnings with net income of $13.0 billion ($4.63 per share, down 7% YoY) but beat adjusted EPS estimates at $5.23. The company posted strong loan growth (up 4% sequentially) and raised 2026 NII guidance to ~$103 billion. Goldman Sachs maintained a Buy rating with a $386 price target, raising 2026-2027 PPNR and EPS estimates. However, the analyst expects JPM shares to remain range-bound until there is clarity on potential credit card APR limits and the Card Competition Act.

GOOG - Diversified technology portfolio, strategic quantum computing research through DeepMind, potential for vertical integration in AI ecosystem
AMJB - Mixed signals: Strong operational results with beat on adjusted EPS, solid loan growth, and raised guidance support positive outlook. However, regulatory uncertainty around credit card APR limits and the Card Competition Act creates near-term headwinds, causing analyst to expect range-bound trading despite maintaining Buy rating. Stock down 1% on publication day.

#JPMorgan Chase #Q4 earnings #net income #EPS #loan growth #net interest income #credit card APR #Card Competition Act #Goldman Sachs #Buy rating

Why Are Bank of America Shares Trading Lower On Wednesday?

Benzinga • Lekha Gupta

Why Are Bank of America Shares Trading Lower On Wednesday?

01/14/2026 12:50 PM • Bank of America shares declined 5% on Wednesday despite beating earnings expectations with net income of $7.6 billion and EPS of 98 cents (vs. 96 cents consensus). Revenue increased 7% YoY to $28.532 billion, also beating estimates. The bank guided for 5-7% net interest income growth in 2026. Goldman Sachs maintained a Buy rating with a $64 price target, citing strong core PPNR and ROTCE performance, though analysts seek clarity on NII drivers and capital return plans.

GOOGL - Diversified technology portfolio, strategic quantum computing research through DeepMind, potential for vertical integration in AI ecosystem
BAC - Despite beating earnings and revenue estimates with strong financial metrics (net income $7.6B, EPS 98 cents, 7% revenue growth), shares traded down 5% on the day. The decline suggests market disappointment with forward guidance or concerns about sustainability of recent performance improvements, particularly regarding net interest income outlook and capital return plans.

#Bank of America #earnings #fourth-quarter results #net interest income #Goldman Sachs #stock decline #guidance

Dave Cantin Group Announces Sale of Midwestern Auto Group to Jeff Wyler Automotive Family; Ferrari and Lamborghini Among 14 Franchises in Historic $500 Million in Total Acquisition Value Transaction

GlobeNewswire Inc. • Dave Cantin Group

Dave Cantin Group Announces Sale of Midwestern Auto Group to Jeff Wyler Automotive Family; Ferrari and Lamborghini Among 14 Franchises in Historic $500 Million in Total Acquisition Value Transaction

01/14/2026 12:50 PM • Jeff Wyler Automotive Family has acquired Midwestern Auto Group in a $500 million deal covering 14 premium and luxury automotive franchises including Ferrari, Lamborghini, Rolls-Royce, and Bentley. The transaction, facilitated by Dave Cantin Group as sell-side advisor, represents one of the largest luxury automotive acquisitions in U.S. history and the largest in Ohio. The acquisition expands Wyler's portfolio to 64 total franchises across the region while keeping the business privately held and Ohio-based.

GS - Provided private wealth management services for the transaction and CEO David Solomon expressed commitment to continued partnership with Dave Cantin Group, indicating successful engagement and relationship strengthening.

#automotive acquisition #luxury dealerships #Ferrari #Lamborghini #succession planning #M&A advisory #private transaction #Ohio dealership

WLTH Investors Have Opportunity to Join Wealthfront Corporation Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

WLTH Investors Have Opportunity to Join Wealthfront Corporation Fraud Investigation with the Schall Law Firm

01/14/2026 12:50 PM • The Schall Law Firm is investigating Wealthfront Corporation (NASDAQ: WLTH) for potential securities law violations, alleging false or misleading statements and inadequate disclosures. The investigation was prompted by a 14% stock price drop following the company's quarterly earnings report, which revealed softening asset flows in November and December.

WLTH - The company is under investigation for potential securities violations and false disclosures. Additionally, the stock experienced a significant 14% decline following disappointing quarterly earnings with weakening asset flows, indicating deteriorating business performance and investor confidence.

#securities fraud #shareholder litigation #Wealthfront #asset flows #earnings report #class action lawsuit

iRhythm Tech's Stock Selloff Went Too Far After Preliminary Update: Analyst

Benzinga • Vandana Singh

iRhythm Tech's Stock Selloff Went Too Far After Preliminary Update: Analyst

01/14/2026 12:43 PM • iRhythm Technologies reported strong preliminary Q4 2025 results with full-year revenue exceeding guidance and 2026 guidance of $870-880M (17-18% YoY growth). However, the stock fell ~20% due to the delay of Zio MCT launch to 2027 and 2026 guidance missing Street expectations. William Blair analyst Brandon Vazquez believes the selloff is overblown and maintains an Outperform rating, adding the stock to their Conviction List at 7x 2026 sales valuation.

BLFS - Mentioned as a key player in the cell and gene therapy infrastructure market without specific growth or investment details
IRTC - Despite a 20% stock decline, the company delivered strong operational results with full-year 2025 revenue exceeding guidance and solid 2026 guidance of $870-880M (17-18% growth). William Blair analyst maintains Outperform rating and believes the selloff is overblown, viewing the company as well-positioned for growth with attractive valuation at 7x 2026 sales. The Zio MCT delay to 2027 is a near-term setback but does not alter the fundamental thesis.

#iRhythm Technologies #Q4 2025 earnings #revenue guidance #Zio MCT delay #stock selloff #analyst rating #digital health

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Benzinga • Vandana Singh

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

01/14/2026 12:36 PM • Amgen announced Phase 2 study results for MariTide, its obesity treatment, showing that participants maintained weight loss achieved in part 1 for an additional 52 weeks on lower monthly or quarterly doses. The drug demonstrated up to 20% average weight loss in people with obesity without Type 2 diabetes and up to 17% in those with the condition. The treatment was well-tolerated with low incidence of nausea and vomiting, with no new safety signals observed. Amgen currently has six Phase 3 studies underway for MariTide across obesity and related conditions.

LZAGY - Listed as a key market player without specific performance indicators in the article
AMGN - Amgen reported positive Phase 2 results for MariTide showing sustained weight loss with less frequent dosing, strong tolerability profile, and no new safety concerns. Analysts view it as a differentiated product with multibillion-dollar peak sales potential and maintain Outperform ratings. Stock showed positive momentum at time of publication.

#MariTide #obesity treatment #weight loss #Phase 2 study #Phase 3 trials #GLP-1 therapies #Type 2 diabetes #cardiometabolic parameters

Why This AI ETF's Top Holdings Could Deliver a 300% return by 2030

The Motley Fool • James Hires

Why This AI ETF's Top Holdings Could Deliver a 300% return by 2030

01/14/2026 12:36 PM • The Global X Artificial Intelligence and Technology ETF (AIQ) is positioned as a solid investment opportunity as the AI industry is projected to reach $826.7 billion by 2030. With a 3-year average annualized return of 36.4%, the ETF's top holdings—Alphabet, Samsung, and Tesla—are highlighted as key drivers of potential growth, supported by strong performance in AI-related segments including autonomous vehicles, chip manufacturing, and autonomous driving technology.

AIQ - The ETF is presented as a solid investment opportunity with strong historical returns (36.4% annualized over 3 years), exposure to high-growth AI companies, and potential for significant future gains based on industry growth projections to $826.7 billion by 2030.

#AI ETF #artificial intelligence #investment #technology stocks #autonomous vehicles #chip manufacturing #market growth

Rexel: Statement relating to the total number of shares and voting rights as of December 31, 2025

GlobeNewswire Inc. • Na

Rexel: Statement relating to the total number of shares and voting rights as of December 31, 2025

01/14/2026 12:00 PM • Rexel reported 296,096,004 shares outstanding as of December 31, 2025, with 293,205,756 exercisable voting rights. The company also announced a biannual share buyback program update and moved forward its full-year 2025 results publication from February 12, 2026 to an earlier date.

HAL - Panel participation suggests standard industry representation
RXEEY - The article contains routine corporate governance disclosures regarding share counts and voting rights, along with administrative updates to the financial calendar. No material business developments, financial performance metrics, or strategic announcements are presented that would warrant a positive or negative sentiment.

#share buyback program #voting rights #treasury shares #financial results #liquidity agreement #NATIXIS ODDO BHF

Custom Ink Reveals 2026 Corporate Swag Trends: Quality Over Quantity

GlobeNewswire Inc. • Na

Custom Ink Reveals 2026 Corporate Swag Trends: Quality Over Quantity

01/14/2026 12:00 PM • Custom Ink's 2026 Swag Trends Survey reveals a significant shift in corporate promotional merchandise strategy, with 67% of buyers prioritizing longevity and quality over volume. Key trends include heavyweight fabrics (62%), garment-dyed colors (50%), and boxy cuts (46%), while wellness items and cozy gear lead non-apparel categories. Made in USA products and sustainability are increasingly important, with 61% rating American-made items as very or extremely important. Standard cotton t-shirts and basic plastic bottles are losing favor as organizations invest in meaningful swag to build team unity and company culture.

ARXCY - Participating in panel discussion indicates standard industry engagement
NKE - Nike is specifically mentioned as a recognized retail brand that corporate buyers prefer for promotional merchandise, with 91% of buyers believing teams feel more valued receiving recognized brands like Nike compared to generic alternatives.

#promotional merchandise #corporate swag #quality over quantity #team unity #sustainability #Made in USA #wellness gear #heavyweight apparel #garment-dyed colors #company culture